reeled in $84.8 million in an initial public offering in Australia. The San Diego-based bioresorbable stent developer’s shares are slated to begin trading on the Australian Securities Exchange ...

C. Michael Gibson talks with Patrick Serruys about TALENT: A Randomized Trial Evaluating an Ultra-Thin Strut Bioresorbable Polymer-Based Coronary Drug-Eluting Stent in an All-Comers Patient Population ...